Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alk-Abello ASCHIX:ALKBC 94 Shiller PE Ratio is 131.07 as of Sep. 07, 2026, which is 20% below its 10-year median of 163.39. GuruFocus rates CHIX:ALKBC with a GF Score™ of 94/100 and a GF Value™ of kr227.25 (Fairly Valued). Among 170 Biotechnology companies, Alk-Abello AS ranks worse than 90.59% on this metric.
As of today (2026-09-07), Alk-Abello AS's current share price is kr221.50. Alk-Abello AS's E10 for the quarter that ended in Jun. 2026 was kr1.69. Alk-Abello AS's Shiller PE Ratio for today is 131.07.
The historical rank and industry rank for Alk-Abello AS's Shiller PE Ratio or its related term are showing as below:
CHIX:ALKBc'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 43.06 Med: 163.39 Max: 379.56
Current: 129.63
During the past years, Alk-Abello AS's highest Shiller PE Ratio was 379.56. The lowest was 43.06. And the median was 163.39.
CHIX:ALKBc's Shiller PE Ratio is ranked worse than 90.59% of 170
companies
in the Biotechnology industry
Industry Median: 33.405
vs CHIX:ALKBc: 129.63
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Alk-Abello AS's adjusted earnings per share data for the three months ended in Jun. 2026 was kr1.500. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is kr1.69 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Alk-Abello AS (CHIX:ALKBc) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Alk-Abello AS Shiller PE Ratio Related Terms
Alk-Abello AS Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALKBC vs VRTX, REGN, MRNA: Shiller PE Ratio Comparison
For the Biotechnology subindustry, Alk-Abello AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS Shiller PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Alk-Abello AS's Shiller PE Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS's E10 for the quarter that ended in Jun. 2026 is calculated as:
For example, Alk-Abello AS's adjusted earnings per share data for the three months ended in Jun. 2026 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Alk-Abello AS (CHIX:ALKBC) has a Shiller PE Ratio of 131.07 as of Sep. 07, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Alk-Abello AS and its competitors. This is 20% below median its historical median of 163.39. Over the past decade, Alk-Abello AS's Shiller PE Ratio has ranged from 43.06 to 379.56. According to the industry distribution chart, Alk-Abello AS ranks #154 out of 170 companies in the Biotechnology industry, placing it in the top 90.6%.
Is Alk-Abello AS's Shiller PE Ratio too high?
Alk-Abello AS's current Shiller PE Ratio of 131.07 is 20% below median its 10-year median of 163.39. Over the past 10 years, this metric has ranged from a low of 43.06 to a high of 379.56. The Biotechnology industry median Shiller PE Ratio is 33.41. Alk-Abello AS's value of 131.07 is 292.4% above this industry median. Based on the distribution chart, Alk-Abello AS ranks #154 out of 170 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alk-Abello AS has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Shiller PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #154 out of 170 companies for Shiller PE Ratio. This places Alk-Abello AS in the lower half of its industry. The industry median Shiller PE Ratio is 33.41. Alk-Abello AS's value of 131.07 is 292.4% above this benchmark. Historically, Alk-Abello AS's own Shiller PE Ratio has ranged from 43.06 to 379.56 over the past decade. While the company's 10-year median is 163.39 vs. the industry median of 33.41, Alk-Abello AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Biotechnology company?
The median Shiller PE Ratio among Biotechnology companies is 33.41, based on 170 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current Shiller PE Ratio of 131.07 is 292.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median Shiller PE Ratio is 33.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current Shiller PE Ratio is 131.07, which is 20% below median its own 10-year median of 163.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Fairly Valued. The stock's GF Value™ is kr227.25, compared to a current price of kr221.50 — trading 2.5% below its estimated fair value. The current Shiller PE Ratio is 131.07, which is 20% below median its 10-year median of 163.39 and 292.4% above the Biotechnology industry median of 33.41. Alk-Abello AS's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current Shiller PE Ratio is 131.07 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be undervalued.
The current stock price of kr221.50 is trading 2.5% below its estimated GF Value™ of kr227.25.
GuruFocus considers Alk-Abello AS to be Fairly Valued.
Key valuation signals for CHIX:ALKBC:
Shiller PE Ratio: 131.07 (20% below median its 10-year median of 163.39)
GF Value™: kr227.25 vs. price of kr221.50 (2.5% below fair value)
Industry Position: 292.4% above the Biotechnology median (#154 of 170)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
94GF Score
Get the complete analysis for CHIX:ALKBC
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
